BioSpace News Archive

NeuroSigma, Inc., a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology for treating neurological and neuropsychiatric disorders, today announced the commencement of a strategic digital marketing partnership with Data360, a leading provider of targeted, online marketing for the healthcare industry.

VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease announced that the company has raised bridge financing to support its 2023 objectives.

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”) today announced the close of its previously announced registered direct offering (the “Registered Direct Offering”) with two healthcare-focused U.S. institutional investors to sell 4,796,206 shares of its common stock (the “Shares”) and warrants to purchase up to 4,796,206 Shares (the “Warrants”), in a concurrent private placement (the “Private Placement”).

Axion BioSystems announces the addition of the Omni Pro 12 to the Omni live-cell imaging product family.

HUTCHMED Limited will be announcing its final results for the year ended December 31, 2022 on Tuesday, February 28, 2023 at 3:30 am Eastern Standard Time / 8:30 am Greenwich Mean Time / 4:30 pm Hong Kong Time.

Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the BIO CEO and Investor Conference being held February 6–9, 2023.

Mr. Patrick Charest, B. Sc., P. Eng., Aplantex’s CEO is pleased to announce that its initial round of financing was successfully completed.

Immuneering Corporation today announced that management will present at Guggenheim’s 2023 Oncology Conference to discuss the company’s pipeline, platform, and business strategy.

First Wave BioPharma, Inc. today announced that the Company will initiate its planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF).

Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).